Shares in Shire Plc fell 2 percent on Monday after the U.S. Food and Drug Administration (FDA) decided not to approve its most important pipeline medicine for dry eye disease and asked for more information.   The news is a blow for Shire, which is to trying to buy Baxalta Inc to forge the leading […]

Berg, a private company that uses artificial intelligence to discover new drugs and diagnostics, will help England’s national genomics project mine DNA and health data from thousands of British citizens for potential drug targets. Berg, based in Boston, was co-founded in 2006 by Silicon Valley real estate billionaire Carl Berg. Since then, it has been […]

CRANBURY, N.J. – Amicus Therapeutics, Inc. (FOLD) inked a deal to acquire the privately-held biopharmaceutical company Scioderm Inc., Inc. in a deal worth up to $847 million, the company announced this morning.   The acquisition places Scioderm’s lead product candidate Zorblisa, a topical cream for the treatment of Epidermolysis Bullosa (EB) into Amicus’ rare and […]

San Francisco-based Medivation, Inc. (MDVN), and San Rafael, Calif.-based BioMarin Pharmaceutical Inc. (BMRN) announced today that they have signed a deal for Medivation to buy all worldwide rights to talazoparib, formerly called BMN 673, for breast cancer treatment. Medivation will take over all research, development, regulatory and commercial activities.   Medivation will pay BioMarin $410 […]

Gainesville, Fla.-based Applied Genetic Technologies Corporation (AGTC) announced yesterday that its collaboration with Biogen, Inc. has now closed. Originally announced on July 2, 2015, the deal has met all the conditions under the Hart-Scott-Rodino Antritrust Improvements Act of 1976 and is good to go.   The deal, announced in July, was a collaboration and licensing […]

AbbVie Inc has bought a priority review voucher from United Therapeutics Corp for $350 million that will allow it to accelerate the review process for one of its drugs. United Therapeutics received a rare pediatric disease priority review voucher in March after its drug, Unituxin, was approved by the U.S. Food and Drug Administration to […]

August 5, 2015By Mark Terry, BioSpace.com Breaking News Staff After Dublin-based Shire (SHPG) publicly announced its intentions of buying Illinois-based Baxalta (BXLT) yesterday in an attempt to convince shareholders to pressure management into considering the deal, analysts are speculating on what a merged Shire and Baxalta would look like. On July 10, 2015, Shire approached […]

AstraZeneca (AZN.L), under pressure from falling sales of older drugs, is selling a medicine for a rare type of cancer to Sanofi (SASY.PA) as it continues a drive to raise cash by divesting certain assets. Sanofi’s rare diseases division Genzyme will pay AstraZeneca up to $300 million for global rights to Caprelsa, including an upfront […]

BOULDER, Colo., July 22, 2015 /PRNewswire/ — AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the […]

Biogen said on Thursday it had forged a deal with AGTC to develop gene-based therapies for a range of eye diseases, marking the company’s entry into opthalmology. Shares of AGTC, formally known as Applied Genetic Technologies Corp, surged 21 percent to $19.75 in morning trading on the Nasdaq after the announcement. Biogen shares were little […]